RecruitingPhase 1NCT06031441

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

A Phase I, Open-Label, Multicenter, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors

Sponsor

Genentech, Inc.

Enrollment

250 participants

Start Date

Nov 27, 2023

Study Type

INTERVENTIONAL

Conditions

Metastatic Solid Tumors Locally Advanced Solid Tumors Recurrent Solid Tumors

Summary

This is a first-in-human Phase I, open-label, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamic, and preliminary anti-tumor activity of RO7566802 as a single agent and in combination with atezolizumab in participants with locally advanced, recurrent, or metastatic incurable solid tumor malignancies. Participants will be enrolled in 2 stages: dose escalation and expansion.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Atezolizumab and a drug called RO7566802 for people with locally advanced solid tumors, metastatic solid tumors, and other related conditions. The study is currently recruiting participants at 18 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRO7566802

RO7566802 solution for infusion will be administered as specified in each treatment arm.

DRUGAtezolizumab

Atezolizumab solution for infusion will be administered as specified in each treatment arm.

Locations(18)

University of Alabama at Birmingham (UAB)

Birmingham, Alabama, United States

Yale Cancer Center

New Haven, Connecticut, United States

Icahn School of Medicine at Mount Sinai (ISMMS)

New York, New York, United States

The Ohio State University

Columbus, Ohio, United States

Magee-Woman's Hospital

Harrisburg, Pennsylvania, United States

SCRI Oncology Partners

Nashville, Tennessee, United States

St Vincent's Hospital Sydney

Darlinghurst, New South Wales, Australia

Peter Maccallum Cancer Centre

Melbourne, Victoria, Australia

British Columbia Cancer Agency - 600 10th Ave W

Vancouver, British Columbia, Canada

Princess Margaret Cancer Centre

Toronto, Ontario, Canada

National University Hospital

Singapore, Singapore

National Cancer Centre

Singapore, Singapore

Addenbrooke's Hospital

Cambridge, United Kingdom

Leicester Royal Infirmary

Leicester, United Kingdom

St Bartholomew's Hospital

London, United Kingdom

Sarah Cannon Research Institute

London, United Kingdom

Churchill Hospital

Oxford, United Kingdom

The Royal Marsden hospital

Sutton, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06031441

Related Trials

A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

NCT069837438 locations

SLR-108 PET Imaging in Subjects With Metastatic Solid Tumors

NCT077289421 location

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

NCT0583632439 locations

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

NCT073973386 locations

BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)

NCT0719351111 locations